Propofol Injectable Emulsion
Brand Names: Propofol Injectable Emulsion Generic
Methodology & AI Transparency ⓘ
Propofol Injectable Emulsion Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 10 mg/mL Injection, Emulsion under FDA code 43598-548, 43598-549 (manufactured/labeled by Dr.
- 2 Real-world patient consensus: Tracked across 10 patient dosage logs with a 89% satisfaction benchmark (RxCUI RXN-43598548-2332).
- 3 Typical cash cost range: Public pharmacy ledger: $14.10 low cash benchmark vs. $36.10 chain retail average ($0.1384/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Propofol Injectable Emulsion): nausea (8.2%), headache (6.9%), dizziness (6.1%).
Ask our AI Specialists anything about Propofol Injectable Emulsion
Propofol Injectable Emulsion Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 10 mg/mL Injection, Emulsion under FDA code 43598-548, 43598-549 (manufactured/labeled by Dr. Reddy's Laboratories, Inc.), Propofol Injectable Emulsion delivers intravenous-route general anesthetic pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Propofol Injectable Emulsion reflects general anesthetic pathway engagement after intravenous-route dosing (10 mg/mL Injection, Emulsion, manufactured/labeled by Dr. Reddy's Laboratories, Inc., NDC 43598-548, 43598-549), supporting titratable maintenance pharmacotherapy.
Following administration (10 mg/mL Injection, Emulsion), Propofol Injectable Emulsion achieves Complete (~100%) parenteral systemic delivery for Propofol Injectable Emulsion (10 mg/mL Injection, Emulsion) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after propofol injectable emulsion administration onset, governed by a Approximately 6–18 hours terminal plasma half-life for Propofol Injectable Emulsion terminal half-life through phase i/ii hepatic conjugation of propofol injectable emulsion coupled with glomerular and tubular renal excretion.
Before initiating Propofol Injectable Emulsion at 10 mg/mL Injection, Emulsion, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving propofol injectable emulsion (general anesthetic); concurrent restricted medications flagged in section 4/7 of the propofol injectable emulsion dailymed monograph (rxn-43598548-2332). Logged tolerability patterns center on nausea (8.2% of reports), headache (6.9% of reports), dizziness (6.1% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Propofol Injectable Emulsion (general anesthetic).
Botanical enzyme modulators may alter oral first-pass exposure of Propofol Injectable Emulsion; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Propofol Injectable Emulsion (general anesthetic)
- Concurrent restricted medications flagged in Section 4/7 of the Propofol Injectable Emulsion DailyMed monograph (RXN-43598548-2332)
Logged Side-Effect Incidence (10 Reports)
Propofol Injectable Emulsion Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Propofol Injectable Emulsion)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing: What a 267-Participant Study Found HSK3486 exhibited non-inferiority anesthesia/sedation compared to propofol in patients undergoing fiberoptic bronchoscopy, and had a good safety profile with a lower incidence of pain on injection. CNS drugs • 2022-03-15 • Phase III Randomized Trial | N = 267 | 93/100 | PMID 35157236 ↗ |
| New Insights on A Multicenter, Randomized, gold-standard blind, Positive-Controlled,: What a 416-Participant Study Found Emulsified isoflurane exhibited non-inferiority of anesthesia/sedation compared to propofol in patients undergoing anesthesia induction. CNS drugs • 2022-12-15 • Phase III Randomized Trial | N = 416 | 93/100 | PMID 36385453 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A The study met its primary objective and endpoint, demonstrating noninferiority of HSK3486 compared with propofol in successful anesthetic induction. Anesthesiology • 2024-04-01 • Phase III Randomized Trial | N = 168 | 88/100 | PMID 38150544 ↗ |
| Faster Wake-Up After a Procedure: How a Newer Sedative Compares to Standard Anesthesia This trial established non-inferior sedation success rate of RT compared with propofol. Journal of gastroenterology and hepatology • 2021-02-15 • Phase III Randomized Trial | N = 384 | 87/100 | PMID 32677707 ↗ |
| New Insights on Ciprofol (HSK3486) versus propofol for the induction of deep sedation during: What a 289-Participant Study Found Pain on injection was less common in the ciprofol group (4.9% vs. Basic & clinical pharmacology & toxicology • 2022-08-15 • Phase III Randomized Trial | N = 289 | 87/100 | PMID 35653554 ↗ |
Propofol Injectable Emulsion Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1384/unit (~$4.15/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $36.10 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $14.10 / mo | View logs ↓ |
Propofol Injectable Emulsion Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Propofol Injectable Emulsion RxNorm Concept ID | RXN-43598548-2332 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1384 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $36.10 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $14.10 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Propofol Injectable Emulsion Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Propofol Injectable Emulsion: FDA labeling (2026-07-01, NDC 43598-548), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Propofol Injectable Emulsion community threads and patient logs by age, biological sex, dosage, and treatment duration.